Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 TrialShengxiang Ren, Caicun Zhou, Wenxiu Yao et al.|Journal of Thoracic Oncology|2021Cited by 311
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trialTao Jiang, Shengxiang Ren, Pingyang Wang et al.|Signal Transduction and Targeted Therapy|2021Cited by 94
B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinomaYanan Cui, Renhua Guo|Journal of Experimental & Clinical Cancer Research|2023Cited by 75
Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world studyRan Li, Xinlin Mu, Jun Li et al.|BMC Cancer|2024Cited by 23
Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung CancerChen Zhang, Renhua Guo|Oxidative Medicine and Cellular Longevity|2023Cited by 16